Watch ASBP. Know when insiders buy.
One email the day a filing lands. Free.
ASBP
Aspire Biopharma Holdings, Inc.
8.87
−0.38 −4.11%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$11MNET CASH —52W 0.16 – 20.48SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $63K | — | -47.7% | −$2.7M | −$1.3M | — | -1.22 | −$2.1M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $28K | — | 20.3% | −$1.6M | −$3.2M | — | -20.57 | −$3M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.8M | −$4.7M | — | -15.95 | −$928K | — | — | Apr 8 |
| Q3 2025 · Sep 30 | — | — | — | −$1.1M | −$1.9M | — | -0.04 | −$1.1M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$800K | −$2M | — | -48.19 | −$1.1M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$15.6M | −$15.9M | — | -504.88 | −$1.8M | — | — | Aug 13 |
| Q4 2024 · Dec 31 | — | — | — | −$668K | −$766K | — | -1.88 | $480K | — | — | Apr 8 |
| Q3 2024 · Sep 30 | — | — | — | −$215K | −$216K | — | -0.01 | −$496K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | — | −$97K | — | — | −$56K | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | — | −$231K | — | — | −$193K | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | — | −$151K | — | — | −$156K | — | — | Apr 7 |
| Q3 2023 · Sep 30 | — | — | — | — | −$69K | — | — | −$125K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6K | -1.9% | −$19.4M | −$24.5M | -394725.1% | -16.38 | −$4.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$1.2M | −$1.3M | — | -1.90 | −$265K | — | — | $13.8M | — |
| FY2023 · to Dec 31 | — | — | — | $4.5M | — | — | −$653K | — | — | $284.9M | — |
| FY2022 · to Dec 31 | — | — | — | $3.3M | — | — | −$1.4M | — | — | — | — |
Every number comes from Aspire Biopharma Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.